Melatonin is implicated in various physiological functions, including anticancer activity. However, the mechanism(s) of its anticancer activity is not well understood. In the present study, we investigated the combined effects of melatonin and arsenic trioxide (ATO) on cell death in human breast cancer cells. Melatonin enhanced the ATO-induced apoptotic cell death via changes in the protein levels of Survivin, Bcl-2, and Bax, thus affecting cytochrome c release from the mitochondria to the cytosol. Interestingly, we found that the cell death induced by co-treatment with melatonin and ATO was mediated by sustained upregulation of Redd1, which was associated with increased production of reactive oxygen species (ROS). Combined treatment with melatonin and ATO induced the phosphorylation of JNK and p38 MAP kinase downstream from Redd1 expression. Rapamycin and S6K1 siRNA enhanced, while activation of mTORC1 by transfection with TSC2 siRNA suppressed the cell death induced by melatonin and ATO treatment. Taken together, our findings suggest that melatonin enhances ATO-induced apoptotic cell death via sustained upregulation of Redd1 expression and inhibition of mTORC1 upstream of the activation of the p38/JNK pathways in human breast cancer cells.
Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine produced in the pineal gland and other organs at night (Stehle et al., 2011) . Melatonin has various biological activities, including strong anti-oxidant and immunomodulatory properties and the ability to modulate circadian rhythms (Reiter, 2004 ,Cassone, 1990 . Moreover, melatonin exerts anti-proliferative, pro-apoptotic, and antiangiogenic activities in various types of cancer (Rondanelli et al., 2013) . In addition, many studies have reported that melatonin has the potential to be a potent combination therapeutic agent to enhance the efficacy of conventional chemotherapeutic agents and to reduce side effects (Lissoni et al., 1999 ,Fan et al., 2010 ,Reiter et al., 2002 .
Arsenic trioxide (ATO) is a chemical with the formula As 2 O 3 , which has been used clinically as part of the standard treatment for patients with acute promyelocytic leukemia (APL) since its original application at our institute in the 1970s (Antman, 2001) . It is currently understood that ATO exerts its anti-cancer activity in various solid tumors, including breast cancer (Luo et al., 2006 ,Alarifi et al., 2013 . ATO induces apoptosis via several mechanisms, including activation of the JNK signaling cascade, inhibition of AKT activity, and induction of oxidative stress (Alarifi et al., 2013 ,Mann et al., 2008 ,Kasukabe et al., 2013 . Because treatment with ATO alone is limited by its toxicity and low efficacy, combining ATO with other anticancer therapeutic agents may provide a rational molecular basis for novel chemotherapeutic strategies. Therefore, in the present study we examined the combined effects of ATO and melatonin on breast cancer cells.
Redd1 (also known as RTP801, DDIT4, and Dig1) was initially identified as hypoxia-inducible factor-1 (HIF-1)-responsive gene in response to various cellular stresses, including hypoxia, DNA damage and other cellular stress stimuli (Brugarolas et al., 2004 ,Ellisen et al., 2002 ,Jin et al., 2009 ). Redd1 has been reported to inhibit mTORC1 activity through the tuberous sclerosis tumor suppressor complex (TSC)1/2 in response to hypoxia and various stresses in both Drosophila and mammalian cells (Brugarolas et al., 2004 ,Corradetti et al., 2005 ). In addition, several studies have shown that Redd1 is implicated in the regulation of ROS (Ellisen et al., 2002 ,Shoshani et al., 2002 . It has been reported that Redd1 is a transcriptional target of p63 and p53, as well as having been implicated in the ROS-mediated regulation of these two tumor suppressor genes (Ellisen et al., 2002) . Moreover, recent studies have suggested that Redd1 plays an important role in the TSC1/TSC2-mediated inhibition of the mammalian target of rapamycin (mTOR) (Brugarolas et al., 2004) . Although increasing results suggests that Redd1 is a novel cell stress-and hypoxiaresponse gene, the molecular mechanisms involved in Redd1 expression remain unclear. In the present study, we showed that melatonin enhances ATO-induced apoptotic cell death of breast cancer cells via sustained upregulation of Redd1 by induced increased ROS generation. Furthermore, we found that the sustained upregulation of Redd1 induced activation of the JNK/p38 apoptotic pathway via mTORC1/S6K1 inhibition in breast cancer cells. These results suggest that melatonin can be useful as a combination anti-cancer agent to enhance the therapeutic effect of ATO for breast cancer therapy by targeting the ROS/Redd1 pathways.
Materials and methods

Cell culture and reagents
The breast cancer cell line used in this study was SK-BR-3 and MDA-MB-231. The cells were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained at 37 C in an atmosphere of 5% CO 2 and 95% air according to standard procedures. The SK-BR-3 and MDA-MB-231 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI-1640) media supplemented with 10% fetal bovine serum (FBS). Melatonin was purchased from Sigma Chemical Company (St. Louis, MO, USA) and was dissolved in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA). Arsenic trioxide (ATO) was purchased from Sigma Chemical Company (St. Louis, MO, USA) and was dissolved in 1 M sodium hydroxide (NaOH). The final concentrations of DMSO or 1 M NaOH in the culture medium never exceeded 0.2%.
Measurement of cell viability
The cell viability was assessed using a 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. The SK-BR-3 and MDA-MB-231 cells were treated with the drugs, following which the MTT reagent was added. After incubation for 1 h at 37 C, the formed formazan crystals were dissolved in dimethyl sulfoxide (DMSO) with constant shaking for 5 min. The absorbance of the solution was then measured with a microplate reader at 540 nm. This assay was conducted in triplicate. The cell viability was calculated as a percentage of viable cells in the drug-treated group versus untreated control using the following equation: Cell viability
Evaluation of cell death
The cell death was analyzed using an annexin V-FITC apoptosis detection kit (Biovision, Milpitas, CA, USA). The cells were stained with the annexin V-FITC and PI according to the manufacturer's instructions. The SK-BR-3 cells were seeded onto 6-well plates at a density of 5 Â 10 4 cells/well and treated with melatonin and/or ATO for 48 h. The cells were collected, washed with cold PBS, and suspended in 500 ml binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, and 2.5 mM CaCl 2 ). Next, the cells were stained with 1 mg/ml annexin V-FITC and 50 mg/ml PI and analyzed with a
FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Combination index (CI)
The drug interaction between ATO and melatonin was assessed using the combination index (CI). The CI was calculated using the Chou-Talalay method (Chou and Talalay, 1984) and CalcuSyn software (Biosoft, Ferguson, MO, USA). A CI of <1 indicates synergistic, a CI of 1 indicates additive, and a CI of >1 indicates antagonistic effects.
Western blotting analysis
Whole-cell lysates were prepared by incubation on ice for 30 min in lysis buffer (50 mM TriseHCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with a protease inhibitor cocktail (Roche, Mannheim, Germany), followed by centrifugation at 12,000Â g for 15 min. The protein concentration in the supernatants was measured using the Bradford method. The protein samples were separated by SDS-PAGE (10e14% acrylamide) and transferred to nitrocellulose membranes. The membranes were blocked in 5% nonfat skim milk and reacted with primary antibodies for cleaved PARP, phospho-S6K, phospho-P38, phospho-MEK (Cell Signaling Technology, Danvers, MA, USA), phospho-Akt, phospho-JNK, Bcl-2, Survivin, mnSOD (Santa Cruz Biotechnologies, Dallas, TX, USA), Redd1 (Proteintech Group Inc., Chicago, IL, USA), Bax, cytochrome c (BD Pharmigen, San Diego, CA, USA), catalase (Abcam, Cambridge, MA, USA) or b-actin (Sigma Aldrich, St Louis, MO, USA). Then, horseradish peroxidase (HRP)-conjugated secondary antibodies were added to the membranes. The immunoreactive bands were visualized with ECL reagents (Amersham Pharmacia, Uppsala, Sweden).
Measurement of ROS generation
ROS were detected using the cell-permeable indicator, 5-(and-6)-carboxy-2 0 ,7'-dichlorodihydrofluorescein diacetate (carboxy-H 2 DCFDA). The SK-BR-3 cells were seeded onto 6-well plates at a density of 5 Â 10 4 cells/well and treated with melatonin and/or arsenic trioxide (ATO) for 6 h after pre-treatment with N-acetyl-Lcysteine (NAC) (10 mM) for 30 min H 2 O 2 (50 mM) was added as a positive control The cells were stained with 1 mM carboxy-H 2 DCFDA at 37 C for 30 min. The stained cells were collected and analyzed using a FACScan flow cytometer. 
Measurement of change in mitochondrial membrane potential (Djm)
Mitochondrial membrane potential (MMP, Djm) was assessed using a mitochondria staining kit (MitoPT, Immunohistochemistry Technologies, Bloomington, MN, USA) based on 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazol-carbocyanine iodide (JC-1), which is a voltage-sensitive lipophilic cationic fluorescence probe. Briefly, the cells were collected, washed in cold PBS, and incubated with 2 mM JC-1 for 15 min. 10 mM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was added as a positive control. The cells were then washed with PBS and analyzed using a FACScan flow cytometer.
Subcellular fractionation
Cytoplasmic extracts were prepared by incubation of the cells in cytoplasmic extraction lysis buffer [10 mM HEPES, 1.5 mM MgCl 2 , Fig. 2 . The combined treatment with melatonin and ATO induces mitochondrial apoptotic cell death via ROS production in the SK-BR-3 cells. SK-BR-3 cells were pretreated with 10 mM NAC for 30 min or trandfected with SOD and catalase gene, followed by 6 h (A) or 48 h (BeD) treatment with or without 2 mM melatonin and with or without 0.5 mM ATO.
NAC blocks melatonin and ATO-induced ROS production (A), and inhibits cell death (B) and mitochondrial dysfunction (D). Oevrexpression of SOD or catalase block melatonin and ATO-induced apoptosis related proteins (C). The data are expressed as the means ± S.D. ***p < 0.001 versus the melatonin-and ATO-treated groups. (A) ROS were detected with carboxy-H 2 DCFDA. (B) Cell death was evaluated by flow cytometry after annexin V and PI staining. The data are expressed as the means ± S.D. **p < 0.05 versus the melatonin-and ATO-treated groups. (C) Cell lysates were prepared and subjected to Western blotting for Redd1, Bac and cleaved PARP. (D) MMP was analyzed by flow cytometry using JC-1. The cytosolic fraction was obtained and subjected to Western blot analysis using an anti-cytochrome c antibody. Fig. 3 . Effects of the combination of melatonin and ATO on the Redd1 signaling in breast cancer cells. The SK-BR-3 cells were pretreated with or without 10 pmol of Redd1 siRNA for 30 min, followed by 48 h of treatment with or without 2 mM melatonin and with or without 0.5 mM ATO. (AeB) Cell lysates were prepared and subjected to Western blotting for Redd1, pAkt and pS6K. (C) The SK-BR-3 cells were treated with 2 mM melatonin and 0.5 mM ATO for the indicated times. Cell lysates were prepared and subjected to Western 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF] on ice for 15 min, followed by centrifugation at 12,000Â g for 10 min, and the resulting supernatant was employed as the cytoplasmic fraction.
Transfection
The transient transfection experiments with pcDNA3.1(þ)-SOD and -catalase DNA were performed using Lipofectamine 3000 according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
siRNAs and transfections
Redd1 (sc-45806), S6K (sc-36165), TSC2 (sc-36762) and control (sc-37007) siRNAs were purchased from Santa Cruz Biotechnology. The transient transfection experiments with siRNAs were performed using Lipofectamine RNAi MAX™ according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
Statistical analysis
All data are presented as the means ± standard deviation (S.D). The statistical significance was tested with Student's t-test using Sigmaplot software (Systat Software Inc., San Jose, CA, USA).
Results
We first investigated the effect of ATO or melatonin on the SK-BR-3 and MDA-MB-231 cell viability. The SK-BR-3 and MDA-MB-231 breast cancer cells were treated with various concentrations of ATO or melatonin for 48 h, and cell viability was determined using the MTT assay. As shown in Fig. 1A , the MTT assays revealed that ATO and melatonin are cytotoxic (more than 25% reduction of cell viability) at concentrations above 0.5 mM and 2 mM, respectively. We therefore examined the combined effect of 0.5 mM ATO and 2 mM melatonin in subsequent experiments. The combined treatment with melatonin (2 mM) and ATO (0.5 mM) significantly suppressed the cell viability compared with either single treatment (Fig 1B, Left) . Next, we examined cell death as assessed by annexin V and propidium iodide (PI) double-staining positivity. As expected, the combination of the two agents significantly increased cell death compared to the single agent treatments (Fig. 1C, Left) . Next, the synergism between melatonin and ATO was evaluated using the combination index (CI) value calculated with Calcusyn software (Fig. 1B and C, Right) . Indeed, the CI value for the combination of 2 mM melatonin and 0.5 mM ATO in SK-BR-3 cells was <1 (CI ¼ 0.212 and 0.779 in the MTT assay and annexin V/PI staining assay, respectively). Cleaved PARP (a marker of apoptosis) was also significantly increased by the combination of melatonin and ATO ( Fig. 1D and E) . The combined treatment with two agents increased the expression of the pro-apoptotic protein Bax, whereas this treatment decreased the expression levels of anti-apoptotic proteins, such as Survivin and Bcl-2 ( Fig. 1D and E) .
Our previous study demonstrated that ATO stimulates ROS production, which subsequently triggers apoptosis (Jin et al., 2006) . In addition, interesting recent studies have indicated that melatonin produces intracellular ROS in tumor cells (Bejarano et al., 2011) . In light of these results, the levels of ROS were measured using ROS fluorescent probe, 5-(and-6)-carboxy-2 0 ,7'-dichlorodihydrofluorescein diacetate (carboxy-H 2 DCFDA). As shown in Fig. 2A , ATO or melatonin induced ROS generation. Furthermore, the enhancement of the ROS generation by the melatonin/ATO combination was abrogated by the free radical scavenger NAC, SOD and catalase. We found that NAC markedly inhibited the induction of cell death by the combination of melatonin and ATO (Fig. 2B) . H 2 O 2 added as positive control resulted in a marked increase in ROS generation. Also, to further investigate whether intracellular ROS are involved melatonin/ATO-induced cell death, we over-expressed SOD or catalase gene by transfection with each of the specific vectors. As shown in Fig 2C, treatment of NAC and transfection with SOD or catalase blocked the melatonin/ATO-induced increase in level of the Bax, Redd1 and cleaved PARP. In agreement with this result, NAC also suppressed the ability of the combination of melatonin and ATO to depolarize the MMP and cause the release of cytochrome c to the cytosol (Fig. 2D) . CCCP added as positive control resulted in a marked increase in loss of MMP. Together, these findings indicate that ROS generation plays a primary role in the ability of the melatonin/ATO combination to induce mitochondrial injury and apoptosis in breast cancer cells.
Recent, many studies have shown that Redd1 is correlated with ROS (Brugarolas et al., 2004 ,Ellisen et al., 2002 . Thus, to determine whether the melatonin and ATO can affect the Redd1 expression, we examined the expression levels of Redd1 protein in SK-BR-3 cells treated with these two agents. As shown Fig. 3A , the combined treatment with the two agents further increased in level of Redd1 protein compared with the single treatments. DMOG added as positive control resulted in increase in Redd1 expression. However, phosphorylation of the Akt and S6K proteins was decreased by melatonin/ATO (Fig. 3B and C) . Importantly, the combined treatment with both agents caused sustained expression of Redd1, but suppressed the phosphorylation of Akt and S6K in time-dependent manner (Fig. 3C) . The induction of cell death by the combined treatment with the two agents was significantly suppressed by Redd1 siRNA (Fig. 3D) . Knock-down of Redd1 using siRNA prevented the melatonin/ATO-induced decreases in the expression of the p-Akt, p-S6K, Survivin and Bcl-2 proteins and the increases in the expression of Bax protein (Fig. 3E) . These results indicate that sustained Redd1 expression by melatonin/ATO is required to induce cell death in the breast cancer cells.
We also observed that the combination of melatonin and ATO induced the phosphorylation of p38 and JNK compared with the single treatments ( Fig. 4A and B) . Furthermore, pretreatment with JNK and p38 inhibitors (SP600125 and SB203580, respectively) blocked the cell death induced by the combined treatment with the two agents (Figs. 4C, D and 5A ). In addition, the pretreatment with the JNK and p38 inhibitors blocked the melatonin/ATOinduced increase in level of the Bax protein and the decrease in the levels of the Survivin and Bcl-2 proteins (Fig. 5B) . In contrast, the pretreatment with the JNK and p38 inhibitors had no effect on the Redd1 levels (Fig. 5A) . However, the activation of p38 and JNK by the combined treatment with the two agents was significantly suppressed by siRNA targeting Redd1 (Fig. 5B) . The above results showed that the combined treatment with melatonin and ATO caused a significant activation of p38 and JNK via expression of Redd1. To more clearly define the involvement of Redd1 downstream signaling in the melatonin/ATO-induced cell death, we firstly pretreated the cells with rapamycin, an mTORC1 inhibitor and then treated them with melatonin and ATO. As shown in in dose-dependent manner. We then investigated whether the Redd1-dependent cell death induced by melatonin/ATO requires the TSC1/2 complex. We also observed that pre-treatment with siRNA targeting TCS2 blocked the melatonin/ATO-induced molecular changes: activation of p38 and JNK, inhibition of MEK, induction of pro-apoptotic proteins and suppression of antiapoptotic proteins. However, the specific inhibition of TSC2 had no effect on the Redd1 level (Fig. 6B) . Additionally, pre-treatment with siRNA targeting TCS2 dramatically blocked the cell death induced by the combined treatment with the two agents (Fig. 6C) . In contrast, pre-treatment with siRNA targeting S6K, a downstream effector of Redd1, further enhanced these molecular changes but not the Redd1 expression (Fig. 6D) . In addition, siRNA targeting S6K further increased the cell death induced by the combination of melatonin and ATO (Fig. 6E) . Overall, these results indicate that the combination of melatonin and ATO induced a sustained upregulation of Redd1 through ROS generation, which led to activation of p38 and JNK via the mTOR/S6K pathways in breast cancer cells (Fig. 6F) .
Discussion
The results in this paper demonstrate a synergistic effect of melatonin and ATO on their anti-cancer activity against breast cancer cells. Such an anticancer effect is due to potentiation of ROSinduced apoptosis via sustained overexpression of Redd1. These results suggest that ROS-inducible chemotherapeutic agents combined with melatonin may improve the therapeutic anti-cancer effect. Furthermore, Redd1 may be a crucial factor in producing an anticancer cascade via melatonin induced-ROS generation.
It is currently established that ATO exerts anti-cancer activity in several solid tumors, including breast cancer (Luo et al., 2006; Alarifi et al., 2013) . Additionally, previous studies have shown that ATO induces apoptosis via activation of JNK and inhibition of AKT pathways as well as the induction of oxidative stress (Alarifi et al., 2013; Mann et al., 2008; Kasukabe et al., 2013) . These results are consistent with the results of the present study. However, because the toxicity and efficacy of ATO alone limits the utility of this agent, our group examined the effects of combinations of ATO The SK-BR-3 cells were treated with 2 mM melatonin and 0.5 mM ATO for the indicated times. Cell lysates were prepared and subjected to Western blotting for pJNK, pP38 and pMEK. (C) The SK-BR-3 cells were pretreated with or without 10 mM PD98059, 10 mM SP600125 or 10 mM SB203580 for 30 min, followed by 48 h of treatment with or without 2 mM melatonin and with or without 0.5 mM ATO. The cell death was evaluated by flow cytometry after annexin V and PI staining. (D) Cell lysates were prepared and subjected to Western blotting for pJNK, pP38, pMEK and cleaved PARP.
with other therapeutic agents. Recently, our studies showed that Sulindac and ATO synergistically enhance apoptosis in A549 and H1299 human lung cancer cells (Jin et al., 2006 ,Jin et al., 2008 . Many other studies have reported that the combination of ATO with selected agents showed synergistic anticancer effects against various tumors, including breast cancers (Rogers et al., 2014 ,Kasukabe et al., 2015 Zhang et al., 2015 ,Zhao et al., 2014 ,Ingram et al., 2015 . Therefore, combining of ATO with other anticancer therapeutic agents might improve the efficacy over single therapy with ATO, which is limited by its toxicity and low efficacy. The combination of ATO with other anticancer therapeutic agents may help overcome the limitations of treatment with ATO alone.
Various anticancer properties of melatonin had been reported in diverse types of cancer (Sainz et al., 2003 ,Cos and Sanchez-Barcelo, 2000 ,Cabrera et al., 2010 ,Bartsch et al., 2000 . Additionally, it has been reported that melatonin showed protective effects against the cytotoxicity of several anticancer agents in normal non-tumor cells (Kim et al., 2012; Fic et al., 2007 ,Hassan et al., 1999 . Thus, the combination of melatonin with other anticancer agents, such as ATO, may achieve an enhanced effect and overcome a limitation in anticancer treatment. However, the precise therapeutic efficacy and mechanism of action of melatonin remain unclear.
Both melatonin and ATO have been shown to induce cancer cell death in many studies and have been combined with other anticancer agents in studies of various types of cancer cells. However, they have never been combined as an anticancer treatment in any cancer type, including breast cancer. In the present study, we hypothesized that the combination of melatonin with ATO might show synergistic anticancer effects. To test this hypothesis, we analyzed the synergistic effect and mechanism of action of this two-agent treatment in breast cancer cells.
In the present study, we demonstrated a synergistic effect between melatonin and ATO on the inhibition of viability and induction of cell death in SK-BR-3 breast cancer cells with CI values of 0.212 and 0.779, respectively. (MDA-MB-231 cells with CI values of 0.521). In contrast, the combined treatment with the two agents had no effect on viability in MCF10A normal breast cells (data not shown).
The combination of melatonin and ATO induced apoptosis of the breast cancer cells, which was observed as an up-regulation in the level of pro-apoptotic proteins, such as Bax, and down-regulation of the levels of anti-apoptotic proteins, including Survivin and Bcl-2, as well as significantly induced increases in the mitochondrial membrane potential and ROS generation. Cellular ROS are essential to cell survival and the regulation of various signaling molecules. Interestingly, a high level of ROS inhibits cell growth, induces cell cycle arrest, and causes apoptosis and necrosis in many tumor cells (Burdon, 1996) . Miller et al. (Miller et al., 2002) were the first to show that ATO can act as an anticancer agent via induction of ROSmediated-apoptotic cell death in cancer cells. As mentioned earlier, our recent results showed that combination of Sulindac and ATO synergistically induce apoptotic cell death via ROS generation in human lung cancer cells (Jin et al., 2006 ,Miller et al., 2002 . Additionally, many studies have reported that melatonin is able to increase intracellular ROS in various cancer cells (Uguz et al., 2012 ,Radogna et al., 2009 . The results of the present study showed a significant and marked rise in intracellular ROS generation after 6 h of combined treatment of melatonin and ATO compared to treatment with the single agents.
Recently, many studies, including our previous work, have shown a function for Redd1 in the regulation of ROS (Brugarolas et al., 2004 ,Ellisen et al., 2002 ,Davies, 2009 ). In agreement with this, we observed that the combined treatment significantly increased the expression of Redd1 and caused its sustained overexpression in breast cancer cells. In addition, siRNA targeting of Redd1 blocked the increased cell death and the levels of the proapoptotic proteins induced by the combined treatment with the two agents. Furthermore, the activation of p38/JNK induced by the combination treatment with the two agents was abolished by Redd1-targeted siRNA. Importantly, this is the first report of an association between melatonin and Redd1.
We are currently pursuing studies to further characterize the effects of these agents in other cancer types. Establishing the mechanism of the specificity could broaden the concept and increase the applicability of melatonin. In this paper, we emphasize that the presented mechanism is defined in the SK-BR-3 and MDA-MD-231 cells.
In summary, our data demonstrate that a combined treatment with melatonin and ATO synergistically induced apoptotic cell death via ROS generation and the sustained upregulation of Redd1 in breast cancer cells. Furthermore, the combination of the two agents promoted an activation of p38 and JNK in the cells. Overall, our findings suggest that the combination of melatonin with ATO may be a promising therapeutic strategy for treating breast cancer. Nonetheless, further studies are needed to determine whether the combination of melatonin and ATO is effective in other types of cancer cells. Additionally, in vivo animal models and pharmacological doses of melatonin and ATO should be used in further studies to corroborate the findings herein.
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